Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
SGMT Stock Chart & Stats
$4.82
-$0.58(-10.41%)
At close: 4:00 PM EST
$4.82
-$0.58(-10.41%)
Day’s Range― - ―
52-Week Range$1.73 - $11.41
Previous CloseN/A
Volume1.06M
Average Volume (3M)394.13K
Market Cap
$149.43M
Enterprise Value$114.48M
Total Cash (Recent Filing)$113.12M
Total Debt (Recent Filing)$78.00K
Price to Earnings (P/E)―
Beta2.92
Next Earnings
May 20, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding31,001,108
10 Day Avg. Volume313,627
30 Day Avg. Volume394,133
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-4.19
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.01
Forecast
1Y Price Target
$26.00Price Target Upside439.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.91
Revenue Forecast (FY)$300.00K
Bulls Say, Bears Say
Bulls Say
Biomarker And Digital Pathology SensitivityAI‑based digital pathology identified fibrosis improvements missed by conventional methods, improving the ability to measure treatment effects and strengthen evidence of clinical benefit.
Phase 1 Safety And PharmacokineticsConsistent Phase 1 safety and pharmacokinetic results with no serious adverse events support advancing the denifanstat plus resmetirom combination into a Phase 2 proof‑of‑concept trial.
Phase 2 Trial Design (non-invasive Endpoints)Regulatory discussions that support using non‑invasive liver tests as primary endpoints could simplify assessments and speed patient enrollment for the planned Phase 2 study in advanced liver fibrosis.
Bears Say
Analyst Conflict Of Interest ConcernsDisclosures that reporting firms do business with covered companies create potential conflicts that could affect the objectivity of analyst reports and investor confidence.
Clinical, Regulatory And Commercial RisksKey risks include possible clinical trial failure, regulatory setbacks, competition from other therapies, execution challenges in commercialization, and intellectual property disputes that could impede value creation.
Financial Runway And Financing RiskCurrent cash resources indicate a limited runway that may require additional financing to fully advance clinical programs, posing dilution risk if capital is raised.
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $1.73 and its highest was $11.41 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $149.43M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is May 20, 2026 which is in 58 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Mar 11, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.432 by $0.142.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.38.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 31,001,108 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.432. Following the earnings report the stock price went up 3.797%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sagimet Biosciences, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (439.42% Upside)
$26.00 (439.42% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 549.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $105.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.01%
12-Months-Change
Fundamentals
Return on Equity
-40.85%
Trailing 12-Months
Asset Growth
-27.32%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Stock 12 Month Forecast
Average Price Target
$26.00
▲(439.42% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
10.84% Insiders
6.02% Mutual Funds
23.61% Other Institutional Investors
54.56% Public Companies and Individual Investors